首页> 外文OA文献 >Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

【2h】

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

机译：用于T细胞急性淋巴细胞白血病的治疗性缺陷的单克隆抗体和双特异性T细胞烘焙剂

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Daniele Caracciolo; Caterina Riillo; Andrea Ballerini; Giuseppe Gaipa; Ludovic Lhermitte; Marco Rossi; Cirino Botta; Eugénie Duroyon; Katia Grillone; Maria Eugenia Gallo Cantafio; Chiara Buracchi; Greta Alampi; Alessandro Gulino; Beatrice Belmonte; Francesco Conforti; Gaetanina Golino; Giada Juli; Emanuela Altomare; Nicoletta Polerà; Francesca Scionti; Mariamena Arbitrio; Michelangelo Iannone; Massimo Martino; Pierpaolo Correale; Gabriella Talarico; Andrea Ghelli Luserna di Rorà; Anna Ferrari; Daniela Concolino; Simona Sestito; Licia Pensabene; Antonio Giordano; Markus Hildinger; Maria Teresa Di Martino; Giovanni Martinelli; Claudio Tripodo; Vahid Asnafi; Andrea Biondi; Pierosandro Tagliaferri; Pierfrancesco Tassone;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease [J] . Sahra Ali, Christian Gisselbrecht, Francesco Pignatti, The oncologist . 2020,第4期

机译：Blinatumomab用于急性淋巴细胞白血病：首批由EMA批准的双特异性T细胞参与抗体用于最小的残留疾病
2. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis [J] . Yu Jian, Wang Wen, Huang He Hematology. . 2019,第1期

机译：双特异性T细胞参录（咬合）抗体Blinatumab用于治疗复发/难治性急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性：全身评测和荟萃分析
3. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis [J] . Jian Yu, Wen Wang, He Huang Hematology . 2019,第1期

机译：双特异性T细胞参与者（咬合）抗体Blinatumab用于治疗复发/难治急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性：系统性评论和荟萃分析
4. Design and Characterization of Bispecific Chemically Self-Assembled Antibody Nanoring(CSAN) T-Cell Engagers That Target CD22+ B- Leukemias or Lymphomas [C] . Jingjing Shen, Adrian Fegan, Daniel A. Vallera, PEGS . 2015

机译：靶向CD22 + B-白血病或淋巴瘤的双特化学自组装抗体纳米（CSAN）T细胞啮合的设计与表征
5. Therapeutic targeting of Hairy and Enhancer of Split 1 (HES1) transcriptional programs in T-cell Acute Lymphoblastic Leukemia [D] . Schnell, Stephanie A. 2015

机译：在T细胞急性淋巴细胞白血病中针对毛发和Split 1（HES1）转录增强子的治疗靶向
6. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts [O] . Judith Feucht, Simone Kayser, David Gorodezki, 2016

机译：PD-L1和CD80 / CD86在白血病母细胞上相反地调节由双特异性T细胞衔接子（BiTE）介导的针对CD19 +小儿急性淋巴细胞白血病的T细胞应答
7. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysis [O] . Jian Yu, Wen Wang, He Huang 2018

机译：双特异性T细胞参与者（咬合）抗体Blinatumab用于治疗复发/难治急性淋巴细胞白血病和非霍奇金淋巴瘤的疗效和安全性：系统性评论和荟萃分析

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

著录项

引文网络

相似文献

相关主题

期刊订阅